⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487755 | 1.00 | — | — | |
| SCHEMBL2487753 | 1.00 | — | — | |
| SCHEMBL2487313 | 0.75 | — | — | |
| SCHEMBL22319221 | 0.75 | — | — | |
| SCHEMBL2487314 | 0.75 | — | — | |
| SCHEMBL1017204 | 0.69 | — | — | |
| SCHEMBL1017141 | 0.69 | — | — | |
| SCHEMBL727639 | 0.69 | — | — | |
| SCHEMBL727638 | 0.69 | — | — | |
| SCHEMBL6068360 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484842-B1 | HALOGEN-CONTAINING METATHESIS CATALYSTS AND METHODS THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11020730-B2 | Halogen-containing metathesis catalysts and methods thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190314799-A1 | HALOGEN-CONTAINING METATHESIS CATALYSTS AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-17 | — | — | US | disclosed |
| EP-2890676-B1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2018-12-05 | — | — | EP | disclosed |
| US-9809537-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-11-07 | — | — | US | disclosed |
| US-9670195-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-06-06 | — | — | US | disclosed |
| US-20170107180-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2017-04-20 | — | — | US | disclosed |
| US-9522883-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2016-12-20 | — | — | US | disclosed |
| US-20150299122-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2015-10-01 | — | — | US | disclosed |
| US-20150218097-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150218147-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2015-08-06 | — | — | US | disclosed |
| EP-2890678-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2015-07-08 | — | — | EP | disclosed |
| EP-2890676-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2015-07-08 | — | — | EP | disclosed |
| EP-2890679-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2015-07-08 | — | — | EP | disclosed |
| EP-2890675-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014032187-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014032188-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014032184-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014032185-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |